Trial Profile
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxalta
- 22 Jun 2016 Status changed from recruiting to completed.
- 22 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 22 Dec 2015 New trial record